Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422569 | 0.83 | CLK1 (0.38) | DYRK1A | |
| SCHEMBL3421275 | 0.81 | CHEK1 (0.43) | CHEK1ACHECDK7MCHR1 | |
| SCHEMBL1750176 | 0.80 | CHEK1 (0.54) | CHEK1ACHECDK7CLK2CLK3 | |
| SCHEMBL3424578 | 0.80 | CHEK1 (0.54) | CHEK1ACHECDK7CLK2CLK3 | |
| SCHEMBL3428325 | 0.79 | CHEK1 (0.42) | CHEK1ACHECDK7MCHR1 | |
| SCHEMBL1750700 | 0.78 | CHEK1 (0.52) | CHEK1ACHECLK2CLK3DYRK1A | |
| SCHEMBL5567692 | 0.77 | PARP1 (0.36) | CHEK1ACHEMCHR1 | |
| SCHEMBL3424207 | 0.74 | EIF4A3 (0.37) | CHEK1 | |
| SCHEMBL3427791 | 0.73 | PARP1 (0.39) | CHEK1ACHE | |
| SCHEMBL1751633 | 0.73 | NR1H2 (0.38) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | CHEK1 242/4885ACHE 1081/4885CDK7 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.